Schedule 13G ownership disclosure

Atara Biotherapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 046513206

Event date: 2025-01-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Panacea Venture Healthcare Fund II, L.P.

    Shares: 550,000 · Class: 9.5%

  • Panacea Venture Healthcare Fund II GP Company, Ltd.

    Shares: 550,000 · Class: 9.5%

  • Panacea Innovation Limited

    Shares: 550,000 · Class: 9.5%

  • James Huang

    Shares: 550,000 · Class: 9.5%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000950170-25-015605
Form type
SCHEDULE 13G
Filer
Atara Biotherapeutics, Inc.
CIK
CIK 1604464
Filed
Feb 06, 2025
Reporting period
Jan 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub